Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER versus CEPHALOTHIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER versus CEPHALOTHIN SODIUM.
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER vs CEPHALOTHIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3 in Gram-negative bacteria, leading to cell lysis and death.
Cephalothin is a first-generation cephalosporin with bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs).
1-2 g IV every 8-12 hours for moderate to severe infections; for febrile neutropenia, 2 g IV every 8 hours.
1-2 g IV every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life ≈2.0–2.3 hours in healthy adults; prolonged to 13–26 hours in severe renal impairment (CrCl <10 mL/min); relevant for dosing interval adjustment.
Terminal elimination half-life: 0.5-1.0 hour in adults with normal renal function. In anuria, prolonged to 2.5-8 hours. Dose adjustment required for CrCl <50 mL/min.
Primarily renal (≈85% unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion). Minor biliary excretion (1-5%). Fecal elimination negligible.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic